Fiduxosin is primarily investigated for its potential therapeutic applications in the treatment of benign prostatic hyperplasia (BPH). It functions as an alpha-1 adrenergic receptor antagonist, which helps relax the smooth muscles in the prostate and bladder neck, thereby improving urine flow and reducing symptoms associated with BPH, such as difficulty in urination, frequent urination, and incomplete bladder emptying. Its selective action on alpha-1 receptors aims to minimize side effects commonly seen with non-selective alpha blockers, making it a promising candidate for managing this condition. Research continues to explore its efficacy and safety profile in clinical settings.